Immunomodulatory effects of macrolides in the lung: Lessons from in-vitro and in-vivo models

Current Pharmaceutical Design

Volumn 10, Issue 25, 2004, Pages 3081-3093

  Tsai, Wan C ^a   Standiford, Theodore J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Cytokines; Immune response; Leukocytes; Lung inflammation; Macrolides

Indexed keywords

AZITHROMYCIN; BAFILOMYCIN; CLARITHROMYCIN; CYCLOSPORIN A; DIRITHROMYCIN; ERYTHROMYCIN; HMR 3004; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; JOSAMYCIN; MACROLIDE; MIDECAMYCIN; NITRIC OXIDE; PHOSPHOLIPASE; PROSTAGLANDIN E2; RAPAMYCIN; RIFAMPICIN; ROKITAMYCIN; ROXITHROMYCIN; SPIRAMYCIN; STEROID; TACROLIMUS; TELITHROMYCIN; TILMICOSIN; TROLEANDOMYCIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BRONCHIOLITIS; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; GRAFT REJECTION; HAEMOPHILUS INFLUENZAE; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEGIONELLA; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION INHIBITION; LUNG ALVEOLITIS; LUNG ALVEOLUS CELL; LUNG ALVEOLUS MACROPHAGE; LUNG CANCER; LUNG DISEASE; LUNG FIBROSIS; LUNG PARENCHYMA; LUNG TRANSPLANTATION; MYCOBACTERIUM; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; STAPHYLOCOCCUS; STROMA CELL; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC FACTORS; LEUKOCYTES; LUNG; MACROLIDES; PNEUMONIA;

EID: 4544273263     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383430     Document Type: Review

References (111)

1. Wildfeuer AH, Laufen D, Muller-Wening O, Haferkamp. Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria in phagocytes. Arzneimittelforschung 1989; 39: 755.
2. Anderson R. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation. J Infect Dis 1989; 159: 966.
3. Torre D, Broggini M, Botta V, Sampietro C, Busarello R, Garberi C. In vitro and ex vivo effects of recent and new macrolide antibiotics on chemotaxis of human polymorphonuclear leukocytes. J Chemother 1991; 3: 236.
4. Labro MT, el Benna J, Babin-Chevaye C. Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils. J Antimicrob Chemother 1989; 24: 561.
5. Lin HC, Wang CH, Liu CY, Yu CT, Kuo HP. Erythromycin inhibits beta2-integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils. Respir Med 2000; 94: 654.
6. Kusano SJ, Kadota S, Kohno K, Iida K, Kawakami T, Morikawa, et al. Effect of roxithromycin on peripheral neutrophil adhesion molecules in patients with chronic lower respiratory tract disease. Respiration 1995; 62: 217.
7. Matsuoka NK, Eguchi A, Kawakami M, Tsuboi Y, Kawabe T, Aoyagi S, et al. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin Exp Immunol 1996; 104: 501.
8. Kawasaki SH, Takizawa T, Ohtoshi N, Takeuchi T, Kohyama H, Nakamura T, et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother 1998; 42: 1499.
9. Abdelghaffar HD, Vazifeh, Labro MT. Comparison of various macrolides on stimulation of human neutrophil degranulation in vitro. J Antimicrob Chemother 1996; 38: 81.
10. Abdelghaffar HD, Vazifeh, Labro MT. Erythromycin A-derived macrolides modify the functional activities of human neutrophils by altering the phospholipase D-phosphatidate phosphohydrolase transduction pathway: L-cladinose is involved both in alterations of neutrophil functions and modulation of this transductional pathway. J Immunol 1997; 159: 3995.
11. Xu GJ, Fujita K, Negayama K, Yuube S, Hojo Y, Yamaji K, et al. Effect of macrolide antibiotics on macrophage functions. Microbiol Immunol 1996; 40: 473.
12. Vazifeh DA, Preira A, Bryskier, Labro MT. Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob Agents Chemother 1998; 42: 1944.
13. Aoshiba KA, Nagai, Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother 1995; 39: 872.
14. Inamura KN, Ohta S, Fukase N, Kasajima, Aoyagi M, The effects of erythromycin on human peripheral neutrophil apoptosis. Rhinology 2000; 38: 124.
15. Adachi TS, Motojima A, Hirata T, Fukuda N, Kihara A, Kosaku H, et al. Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5. J Allergy Clin Immunol 1996; 98: S207.
16. Grdisa M, Lopotar N, Pavelic K. Effect of a 17-member azalide on tumor cell growth. Chemotherapy 1998; 44: 331.
17. Hotta M. Neutrophil chemotactic activity in cryptogenic organizing pneumonia and the response to erythromycin. Kurume Med J 1996; 43: 207.
18. Lakritz J, Wilson WD, Watson JL, Hyde DM, Mihalyi J, Plopper CG. Effect of treatment with erythromycin on bronchoalveolar lavage fluid cell populations in foals. Am J Vet Res 1997; 58: 56.
19. Chin AC, Morck DW, Merrill JK, Ceri H, Olson ME, Read RR, et al. Anti-inflammatory benefits of tilmicosin in calves with Pasteurella haemolytica-infected lungs. Am J Vet Res 1998; 59: 765.
20. Fajt VR, Apley MD, Roth JA, Frank DE, Brogden KA, Skogerboe TL, et al. The effects of danofloxacin and tilmicosin on neutrophil function and lung consolidation in beef heifer calves with induced Pasteurella (Mannheimia) haemolytica pneumonia. J Vet Pharmacol Ther 2003; 26: 173.
21. Capelli A, Capelli O, Azzolini L, Richeldi L, Prandi E, Velluti G. Activities of human alveolar macrophages (HAMs). Note 1: Observations on phagocytosis and bacterial killing in the presence of miocamycin. Chemioterapia 1988; 7: 89.
22. Luna-Herrera J, Reddy VM, Daneluzzi D, Gangadharam PR. Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 1995; 39: 2692.
23. Heming TA, Traber DL, Hinder F, Bidani A. Effects of bafilomycin A1 on cytosolic pH of sheep alveolar and peritoneal macrophages: evaluation of the pH-regulatory role of plasma membrane V-ATPases. J Exp Biol 1995; 198 (Pt 8): 1711.
24. Chen B, Jiang L, Zhao W, Yu R, Hou XM. Ameliorating effect of erythromycin on bleomycin-induced pulmonary fibrosis: role of alveolar macrophage activation and cytokine release. Respirology 1997; 2: 151.
25. Li Y, He B, Wang H. [The effect of erythromycin on NF-kappa B activation and cytokines mRNA expression in bleomycin-induced pulmonary fibrosis in rats]. Zhonghua Jie He He Hu Xi Za Zhi 1999; 22: 725.
26. Sunazuka T, Takizawa H, Desaki M, Suzuki K, Obata R, Otoguro K, et al. Effects of erythromycin and its derivatives on interleukin-8 release by human bronchial epithelial cell line BEAS-2B cells. J Antibiot (Tokyo) 1999; 52: 71.
27. Ichiyama T, Nishikawa M, Yoshitomi T, Hasegawa S, Matsubara T, Hayashi T, et al. Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 2001; 45: 44.
28. Tamaoki J, Kondo M, Kohri K, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J Immunol 1999; 163: 2909.
29. Kohri K, Tamaoki J, Kondo M, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. Eur Respir J 2000; 15: 62.
30. Katoh S, Matsubara Y, Taniguchi H, Fukushima K, Mukae H, Kadota J, et al. Characterization of CD44 expressed on alveolar macrophages in patients with diffuse panbronchiolitis. Clin Exp Immunol 2001; 126: 545.
31. Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epitheliall cells. Eur Respir J 1995; 8: 1451.
32. Takizawa H, Desaki M, Ohtoshi T, Kikutani T, Okazaki H, Sato M, et al. Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem Biophys Res Commun 1995; 210: 781.
33. Abe S, Nakamura H, Kato S, Tomoike H, Takeda H. [Effect of macrolides on 1L-8 gene expression by cultured airway epithelial cells]. Jpn J Antibiot 1998; 51 Suppl: 120.
34. Abe S, Nakamura H, Inoue S, Takeda H, Saito H, Kato S, et al. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2000; 22: 51.
35. Desaki M, Takizawa H, Ohtoshi T, Kasama T, Kobayashi K, Sunazuka T, et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000; 267: 124.
36. Ge N, Nakamura Y, Nakaya Y, Sone S. Interferon-gamma activates outwardly rectifying chloride channels in the human bronchial epithelial cell line BEAS-2B. J Med Invest 2001; 48: 97.
37. Kato T, Yamada M, Kohara Y, Ikekita M, Yonmiya T. Effect of azithromycin on cytokine production in human bronchial epithelial cell line, BEAS-213. Japan J Antibiot 2001; 54 Suppl C: 83.
38. Miyanohara T, Ushikai M, Matsune S, Ueno K, Katahira S, Kurono Y. Effects of clarithromycin on cultured human nasal epithelial cells and fibroblasts. Laryngoscope 2000; 110: 126.
39. Dupont MJ, Lapointe JR. Effect on Pseudomonas aeruginosa alginate expression of direct plating and culture of fresh cystic fibrosis sputum on to pseudomonas isolation agar containing subinhibitory concentrations of roxithromycin and rifampicin. J Antimicrob Chemother 1995; 36: 231.
40. Kobayashi O, Ota M, Watanabe H, Kobayashi H. Actions of macrolide antibiotics on alginate production by Pseudomonas aeruginosa. Jpn J Antibiot 1997; 50 Suppl: 95.
41. Takeyama K, Tamaoki A, Kondo M, Aoshiba K, Nakata J, Isono K, et al. Effect of macrolide antibiotics on MUC5AC production in human bronchial epithelial cells. Jpn J Antibiot 2001; 54 Suppl C: 52.
42. Irokawa T, Sasaki T, Shimura S, Sasamori K, Oshiro T, Nara M, et al. Cholinomimetic action of macrolide antibiotics on airway gland electrolyte secretion. Am J Physiol 1999; 276: L951.
43. Gant TW, O'Connor CK, Corbitt R, Thorgeirsson U, Thorgeirsson SS. In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol 1995; 133: 269.
44. Yamanaka Y, Tamari M, Nakahata T, Nakamura Y. Gene expression profiles of human small airway epithelial cells treated with low doses of 14- and 16-membered macrolides. Biochem Biophys Res Commun 2001; 287: 198.
45. Takizawa H, Desaki M, Ohtoshi T, Kawasaki S, Kohyama T, Sato M, et al. Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. Eur Respir J 1998; 12: 57.
46. Feldman C, Anderson R, Theron A, Mokgobu I, Cole P J, Wilson R. The effects of ketolides on bioactive phospholipid-induced injury to human respiratory epithelium in vitro. Eur Respir J 1999; 13: 1022.
47. Tagaya E, Tamaoki J, Konno K. Erythromycin inhibits cholinergic neuro-effector transmission in canine airway smooth muscle. Res Commun Mol Pathol Pharmacol 1994; 85: 181.
48. Tamaoki J, Tagaya E, Sakai A, Konno K. Effects of macrolide antibiotics on neurally mediated contraction of human isolated bronchus. J Allergy Clin Immunol 1995; 95: 853.
49. Beers MF Inhibition of cellular processing of surfactant protein C by drugs affecting intracellular pH gradients. J Biol Chem 1996; 271: 14361.
50. Wissel H, Lehfeldt A, Klein P, Muller T, Stevens PA. Endocytosed SP-A and surfactant lipids are sorted to different organelles in rat type II pneumocytes. Am J Physiol Lung Cell Mol Physiol 2001; 281: L345.
51. Cho T, Senda K, Suda T, Kanai M, Nakamura H. Effects of EM on the intracellular Ca 2+ response in A549 cells. Jpn J Antibiot 2000; 53 Suppl A: 14.
52. Zhao DM, Xue HH, Chida K, Suda T, Oki Y, Kanai M, et al. Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells. Am J Physiol Lung Cell Mol Physiol 2000; 278: L726.
53. Belham CM, Scott PH, Twomey DP, Gould GW, Wadsworth RM, Plevin R. Evidence that thrombin-stimulated DNA synthesis in pulmonary arterial fibroblasts involves phosphatidylinositol 3-kinase-dependent p70 ribosomal S6 kinase activation. Cell Signal 1997; 9: 109.
54. Nonaka M, Pawankar R, Tomiyama S, Yagi T. A macrolide antibiotic, roxithromycin, inhibits the growth of nasal polyp fibroblasts. Am J Rhinol 1999; 13: 267.
55. Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 2000; 14: 143.
56. Yatsunami J, Fukuno Y, Nagata M, Tominaga M, Aoki S, Tsuruta N, et al. Antiangiogenic and antitumor effects of 14-membered ring macrolides on mouse B16 melanoma cells. Clin Exp Metastasis 1999; 17: 361.
57. Yatsunami J, Fukuno Y, Nagata M, Tsuruta N, Aoki S, Tominaga M, et al. Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells. Cancer Lett 1999; 147: 17.
58. Yatsunami J, Tsuruta N, Hara N, Hayashi S. 1998. Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic. Cancer Lett 131: 137.
59. Mitsuyama T, Furuno T, Hidaka K, Tanaka T, Abe M, Hara N. Inhibition by erythromycin of human pulmonary artery endothelial cell injury induced by human neutrophils. Respiration 1997; 64: 206.
60. Mitsuyama T, Hidaka K, Furuno T, Hara N. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide. Int Arch Allergy Immunol 1997; 114: 111.
61. Mitsuyama T, Hidaka K, Furuno T, Hara N. Release of nitric oxide and expression of constitutive nitric oxide synthase of human endothelial cells: enhancement by a 14-membered ring macrolide. Mol Cell Biochem 1998; 181: 157.
62. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156.
63. Tamaoki J, Tagaya E, Yamawaki I, Sakai N, Nagai A, Konno K. Effect of erythromycin on endotoxin-induced microvascular leakage in the rat trachea and lungs. Am J Respir Crit Care Med 1995; 151: 1582.
64. Tamaoki J, Takeyama K, Yamawaki I, Kondo M, Konno K. Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Am J Physiol 1997; 272: L15.
65. Suzaki H, Asano K, Ohki S, Kanai K, Mizutani T, Hisamitsu T. Suppressive activity of a macrolide antibiotic, roxithromycin, on pro-inflammatory cytokine production in vitro and in vivo. Mediators Inflamm 1999; 8: 199.
66. Ose EE, Tonkinson LV. Single-dose treatment of neonatal calf pneumonia with the new macrolide antibiotic tilmicosin. Vet Rec 1988; 123: 367.
67. Gourlay RN, Thomas LH, Wyld SG, Smith CJ. Effect of a new macrolide antibiotic (tilmicosin) on pneumonia experimentally induced in calves by Mycoplasma bovis and Pasteurella haemolytica. Res Vet Sci 1989; 47: 84.
68. + disease. J Antimicrob Chemother 1989; 24: 397.
69. + disease using immunocompromised A/J mice. Antimicrob Agents Chemother 2000; 44: 1333.
70. Azoulay-Dupuis E, Vallee E, Bedos JP, Muffat-Joly M, Pocidalo JJ. Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother 1991; 35: 1024.
71. Girard AE, Cimochowski CR, Faiella JA. The comparative activity of azithromycin, macrolides and amoxycillin against streptococci in experimental infections. J Antimicrob Chemother 1993; 31 Suppl E: 29.
72. Ishida K, Kaku M, Irifune K, Mizukane R, Takemura H, Yoshida R, et al. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994; 38: 790.
73. Derouin F. New pathogens and mode of action of azithromycin: Toxoplasma gondii. Pathol Biol (Paris) 1995; 43: 561.
74. Romand S, Bryskier A, Moutot M, Derouin F. In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii. J Antimicrob Chemother 1995; 35: 821.
75. Brun-Pascaud M, Chau F, Derouin F, Girard PM. Experimental evaluation of roxithromycin combined with dapsone or sulphamethoxazole on Pneumocystis carinii and Toxoplasma gondii dual infections in a rat model. J Antimicrob Chemother 1998; 41 Suppl B: 57.
76. Harindran J, Chakraborty KK, Naik SR. Preparation, relative toxicity and therapeutic efficacy in mice and rats of liposomal HA-1-92, a new oxohexaene polyene macrolide antibiotic. J Pharm Pharmacol 1999; 51: 771.
77. Duong M, Simard M, Bergeron Y, Bergeron MG. Kinetic study of the inflammatory response in Streptococcus pneumoniae experimental pneumonia treated with the ketolide HMR 3004. Antimicrob Agents Chemother 2001; 45: 252.
78. Hardy RD, Rios AM, Chavez-Bueno S, Jafri HS, Hatfield J, Rogers BB, et al. Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. Antimicrob Agents Chemother 2003; 47: 1614.
79. Sato K, Suga M, Akaike T, Fujii S, Muranaka H, Doi T, et al. Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. Am J Respir Crit Care Med 1998; 157: 853.
80. Yanagihara K, Tomono K, Sawai T, Hirakata Y, Kadota J, Koga H, et al. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997; 155: 337.
81. Yanagihara K, Tomono K, Kuroki M, Kaneko Y, Sawai T, Ohno H, Miyazaki Y, et al. Intrapulmonary concentrations of inflammatory cytokines in a mouse model of chronic respiratory infection caused by Pseudomonas aeruginosa. Clin Exp Immunol 2000; 122: 67.
82. Kaneko Y, Yanagihara K, Seki M, Kuroki M, Miyazaki Y, Hirakata Y, et al. Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis. Am J Physiol Lung Cell Mol Physiol 2003; 285: L847.
83. Nelson S, Summer WR, Terry PB, Warr GA, Jakab GJ. Erythromycin-induced suppression of pulmonary antibacterial defenses. A potential mechanism of superinfection in the lung. Am Rev Respir Dis 1987; 136(5): 1207-12.
84. Kobayashi T, Tateda K, Matsumoto T, Miyazaki S, Watanabe A, Nukiwa T, et a]. Macrolide-treated Pseudomonas aeruginosa induces paradoxical host responses in the lungs of mice and a high mortality rate. J Antimicrob Chemother 2002; 50: 59.
85. Akutsu I, Fukuda T, Numao T, Makino S. Inhibitory effect of FK-506 on the development of late asthmatic response and on the increased bronchial responsiveness. Arerugi 1990; 39: 605.
86. Francischi JN, Conroy DM, Cloutier S, Sirois P. Reduction of Sephadex-induced lung inflammation and bronchial hyperreactivity by rapamycin. Braz J Med Biol Res 1993; 26: 1105.
87. Konno S, Asano K, Kurokawa M, Ikeda K, Okamoto K, Adachi M. Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. Int Arch Allergy Immunol 1994; 105: 308.
88. Mori A, Okudaira H, Kobayashi N, Akiyama K. Selective regulation of T cell IL-5 synthesis by OM-01, JTE-711 and p38 MAP kinase inhibitor: independent control of Th2 cytokines, IL-4 and IL-5. Int Arch Allergy Immunol 2001; 124: 172.
89. Tamaoki J, Nakata J, Takeda Y, Takemura H, Tagaya E, Konno K. [Effect of macrolide antibiotics on airway goblet hypersecretion in guinea pigs]. Kansenshogaku Zasshi 1996; 70: 591.
90. Azuma A, Furuta T, Enomoto T, Hashimoto Y, Uematsu K, Nukariya N, et al. Preventive effect of erythromycin on experimental bleomycin-induced acute lung injury in rats. Thorax 1998; 53: 186.
91. Barnes PJ. Immunomodulation as asthma therapy: where do we stand? Eur Respir J Suppl 1996; 22: 154s.
92. Kawashima M, Yatsunami J, Fukuno Y, Nagata M, Tominaga M, Hayashi S. Inhibitory effects of 14-membered ring macrolide antibiotics on bleomycin-induced acute lung injury. Lung 2002; 180: 73.
93. Li Y, Azuma A, Takahashi S, Usuki J, Matsuda K, Aoyama A, et al. Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration: role in preventing lung injury and fibrosis in bleomycin-challenged mice. Chest 2002; 122: 2137.
94. Simler NR, Howell DC, Marshall RP, Goldsack NR, Hasleton PS, Laurent GJ, et al. The rapamycin analogue SDZ RAD attenuates bleomycin induced pulmonary fibrosis in rats. Eur Respir J 2002; 19: 1124.
95. Hamada K, Kita E, Sawaki M, Mikasa K, Narita N. Antitumor effect of erythromycin in mice. Chemotherapy 1995; 41: 59.
96. Hamada K, Sakamoto M, Mikasa K, Teramoto M, Mori K, Tsujimoto M, et al. Evaluation of antineoplastic effect of CAM (clarithromycin) in a mouse model inoculated with lung cancer cells. Jpn J Antibiot 1997; 50 Suppl: 28.
97. Kokubo Y, Shibuya M, Hino M, Azuma A, Aoyama S, Matsuda K, et al. Effects of clarithromycin on experimental pulmonary metastasis. Jpn J Antibiot 1997; 50 Suppl: 35.
98. Hamada K, Mikasa K, Yunou Y, Kurioka T, Majima T, Narita N, et al. Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. Chemotherapy 2000; 46: 49.
99. Aoki M, Hitomi S, Wada H, Inui K, Yamazaki F, Yokomise H, et al. Histological observations of immunosuppressive effects of FK-506 in canine lung allotransplantation. Bull Chest Dis Res Inst Kyoto Univ 1989; 22: 65.
100. Saitoh Y, Fujisawa T, Ogawa T, Urabe N, Yamaguchi Y, Kimizuka G. Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. Jpn J Surg 1990; 20: 205.
101. Katayama Y, Takao M, Onoda K, Hiraiwa T, Yada I, Namikawa S, et al. Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation. Transplant Proc 1991; 23: 349.
102. Blazar BR, Taylor PA, Snover DC, Sehgal SN, Vallera DA. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J Immunol 1993; 151: 5726.
103. Hausen B, Ikonen T, Briffa N, Berry GJ, Christians U, Robbins RC, et al. Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation 2000; 69: 76.
104. Salminen US, Maasilta PK, Taskinen EI, Alho HS, Ikonen TS, Harjula AL. Prevention of small airway obliteration in a swine heterotopic lung allograft model. J Heart Lung Transplant 2000; 19: 193.
105. Kaji M, Inoue K, Kinoshita H. Effects of long-term preoperative administration of low-dose erythromycin on warm ischemia-reperfusion pulmonary injury. Nihon Kokyuki Gakkai Zasshi 1998; 36: 939.
106. Yamamoto K, Mori A, Nakahama T, Ito M, Okudaira H, Miyamoto T. Experimental treatment of autoimmune MRL-1pr/1pr mice with immunosuppressive compound FK506. Immunology 1990; 69: 222.
107. Miyajima M, Suga M, Nakagawa K, Ito K, Ando M. Effects of erythromycin on experimental extrinsic allergic alveolitis. Clin Exp Allergy 1999; 29: 253.
108. Labro MT. Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales". Clin Micro Reviews 2000; 13: 615.
109. Farina C, Gagliardi S. Selective inhibition of osteoclast vacuolar H(+)-ATPase. Curr Pharm Design 2002; 8(23): 2033-48.
110. Gottlieb D. Cytokine manipulation of the immune response in the treatment of human acute leukaemia. Curr Pharm Design 2002; 8(5): 419-31.
111. Pullerits T. Cytokine modulation for anti-allergic treatment. Curr Pharm Design 2002; 8(20): 1845-53.